These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23880711)

  • 1. Efficacy of bisphosphonates and other bone-targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers.
    Karim SM; Brown J; Zekri J
    Clin Adv Hematol Oncol; 2013 May; 11(5):281-7. PubMed ID: 23880711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S; Lyseng-Williamson KA
    Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for malignancy-related bone disease: current status, future developments.
    Body JJ
    Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone markers for monitoring efficacy in patients 
with bone metastases receiving zoledronic acid: 
a review of published data.
    Huang Q; Ouyang X
    Int J Biol Markers; 2013 Sep; 28(3):242-8. PubMed ID: 23661577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid in the management of metastatic bone disease.
    Santini D; Fratto ME; Vincenzi B; Galluzzo S; Tonini G
    Expert Opin Biol Ther; 2006 Dec; 6(12):1333-48. PubMed ID: 17223741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
    Lipton A
    Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S14-20. PubMed ID: 17683649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
    Xie F; Hopkins R; Burke N; Tarride JE; Goeree R
    Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of bone metastases in prostate cancer: a review.
    Bienz M; Saad F
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Bisphosphonates in Breast Cancer Therapy.
    Goldvaser H; Amir E
    Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 13. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
    Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
    Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bisphosphonates in oncology].
    Kurth AA; Heidenreich A; Diel I
    Orthopade; 2007 Feb; 36(2):131-5. PubMed ID: 17252255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-targeted therapies for cancer patients and bone cell biology: where do we stand?
    Berenson JR
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):405-6. PubMed ID: 25319276
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
    Miller K; Steger GG; Niepel D; Lüftner D
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.